{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-021110","form_type":"8-K","ticker":"AQST","cik":"0001398733","company_name":"Aquestive Therapeutics, Inc.","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.238511+00:00","generated_at":"2026-06-02T17:19:42.669008+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Aquestive Therapeutics reports Q1 2024 results, FDA approval of Libervant, and progress on Anaphylm","bullets":["Met all endpoints in Phase 3 pivotal study for Anaphylm (epinephrine) Sublingual Film compared to EpiPen and other injectors.","Received FDA approval for Libervant (diazepam) Buccal Film in patients ages 2-5, now available in multiple strengths.","Completed $77.5M underwritten public offering with institutional investors, extending cash runway into 2026.","Total revenues increased to $12.1M in Q1 2024 from $11.1M in Q1 2023; net loss was $12.8M.","On track to file Anaphylm NDA with FDA by end of 2024, with remaining studies expected by Q3 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-021110","json":"https://secwatch.observer/filing/0001628280-24-021110.json","markdown":"https://secwatch.observer/filing/0001628280-24-021110.md","text":"https://secwatch.observer/filing/0001628280-24-021110.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1398733/000162828024021110/0001628280-24-021110-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1398733/000162828024021110/aqst-20240507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T17:19:42.669008+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2ef03a9d6e215c6d82debc00a9f6c31e71574d89","claim":"Aquestive Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.","evidence_excerpt":"Aquestive Therapeutics, Inc. (the “Company”) issued a press release announcing its reported financial results for the first quarter ended March 31, 2024 and provided an update on recent developments in its business.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1398733/000162828024021110/0001628280-24-021110-index.htm","confidence":0.8,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}